BeOne Medicines drug Beqalzi has accelerated FDA approval for treating relapsed or refractory mantle cell lymphoma, a type of blood cancer. The regulatory nod opens the door to potentially compete against Venclexta, a blockbuster cancer drug marketed by AbbVie and Roche.
The post FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer Drug appeared first on MedCity News.
